Fostera™ PCV MH Licensed for Industry-leading 23-week Duration of Immunity
Combination vaccine gives swine industry effective, convenient option
FLORHAM PARK, N.J., Aug. 20, 2014 — Fostera™ PCV MH — the porcine circovirus (PCV) and Mycoplasma hyopneumoniae (M. hyo) combination vaccine that was built from the ground up by Zoetis — now has the longest demonstrated duration of immunity (DOI) to help protect pigs from porcine circovirus-associated disease (PCVAD) caused by PCV Type 2 (PCV2). The U.S. Department of Agriculture has granted the combination vaccine the extended label claim of at least 23 weeks of protection against PCV2, which is three weeks longer than any other PCV2 vaccine on the market.
“PCVAD continues to be one of the most economically harmful swine diseases. Affected pigs suffer from progressive weight loss, increased mortality and other clinical impacts, which takes a toll on producers’ productivity and profitability,” said Darrell Neuberger, DVM, Pork Technical Services, Zoetis. “Now, with a vaccine that offers at least 23 weeks of immunity, producers have another tool to help their pigs realize the full market potential with convenience and flexibility.”
Introduced in November 2013, Fostera PCV MH was developed to help protect pigs from PCVAD and enzootic pneumonia caused by M. hyo. In clinical research studies of the flexible one- and two-dose protocols, Fostera PCV MH has been demonstrated to aid in preventing viremia, lymphoid depletion and colonization of lymphoid tissue caused by PCV2; and as an aid in reducing PCV2 virus shedding and enzootic pneumonia caused by M. hyo.
Unlike other combination vaccines that require field mixing, the one-bottle formulation of Fostera PCV MH allows the convenience of a one-dose program or the flexibility of a two-dose program. Fostera PCV MH is licensed for administration of pigs 3 weeks of age or older by a single 2 mL intramuscular dose or two 1 mL intramuscular doses spaced two weeks apart.
“We strive to bring solutions to producers and veterinarians through innovative techniques and continued research,” Dr. Neuberger said. “We will continue to invest in our existing products as well as new technology and research to continue that commitment for our customers.”
For more information on Fostera PCV MH, visit zoetisus.com/fosteraPCVMH or talk with your veterinarian or local Zoetis representative.
Zoetis (zō-EH-tis) is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 60 years of experience in animal health, Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products and genetic tests and supported by a range of services. In 2013, the company generated annual revenues of $4.6 billion. With approximately 9,800 employees worldwide at the beginning of 2014, Zoetis has a local presence in approximately 70 countries, including 27 manufacturing facilities in 10 countries. Its products serve veterinarians, livestock producers and people who raise and care for farm and companion animals in 120 countries. For more information, visit www.zoetisUS.com.
Zoetis is the proud sponsor, with the Smithsonian Institution Traveling Exhibition Service, the American Veterinary Medical Association and the American Veterinary Medical Foundation, of the mobile educational exhibit Animal Connections: Our Journey Together. Families visiting the exhibit will explore the vast bonds between people and animals and learn about the important role veterinarians play in protecting animal and human health.
For further information, Contact:
- Belgium (French)
- Belgium (Dutch)
- Costa Rica
- Czech Republic
- New Zealand
- South Africa
- South Korea
- United Kingdom
- United States